Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6064-6069

  Barbareschi, Mattia ^a   Buttitta, Fiamma ^b   Felicioni, Lara ^b   Cotrupi, Sabrina ^a   Barassi, Fabio ^b   Del Grammastro, Maela ^b   Ferro, Antonella ^a   Palma, Paolo Dalla ^a   Galligioni, Enzo ^a   Marchetti, Antonio ^b  

^a SANTA CHIARA HOSPITAL   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; UNIVARIATE ANALYSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; TREATMENT OUTCOME;

EID: 35948964043     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0266     Document Type: Article

References (21)

1. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
2. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9.
3. Kang S, Bader AG, Zhao L, Vogt PK. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 2005;4:578-81.
4. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82.
5. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
6. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73.
7. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005;65:10992-1000.
8. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
9. Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006;208:350-5.
10. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006;96:91-5.
11. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976;3:2303-8.
12. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65.
13. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8.
14. Saal LH, Holm K, Maurer M, et al. PIK3C A mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9.
15. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007;15:408-14.
16. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 2002;87:1105-11.
17. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-9.
18. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis p53 mutations and histological type of invasive breast carcinoma. Ann N Y Acad Sci 1993;698:114-9.
19. Shekar SC, Wu H, Fu Z, et al. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem 2005;280:27850-5.
20. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562-7.
21. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-79.